Boston-based Dana Farber Cancer Institute received the highest linear mean score for physician communication out of 11 cancer hospitals exempt from reporting to Medicare’s Inpatient Prospective Payment System, according to CMS data published Nov. 26. Eleven cancer hospitals are required…
The Latest
Duarte, Calif.-based City of Hope and Eli Lilly have partnered on an oncology-based pharmacy residency program. Wafa Samara, PharmD, vice president and chief pharmacy officer at City of Hope, shared news of the partnership in a Dec. 29 LinkedIn post. …
In a year marked by scientific breakthroughs, some of the most meaningful changes in oncology happened not in the lab — but at the bedside. Leaders say 2025 was the year AI-enabled innovation in care delivery began to rival discovery…
Three states have outlined plans to address cancer care access as part of their participation in the new CMS Rural Health Transformation Program. The application window for the program ran from Sept. 15 to Nov. 5., and final awards were…
Charleston-based Medical University of South Carolina has opened a new hematology and oncology clinic. The clinic is the system’s first hematology and oncology clinic in Lancaster, S.C., according to a Dec. 29 news release from the hospital. The facility offers…
A multicancer early detection blood test increased cancer detection rates more than sevenfold when provided alongside standard breast, colorectal, cervical and lung cancer screening in a clinical trial setting. The PATHFINDER 2 trial was led by principal investigator Nima Nabavizadeh,…
The Women’s Choice Award has recognized 465 U.S. healthcare organizations for providing the highest standard of cancer care through its annual “Best Hospitals for Cancer Care” list. Forty fewer hospitals were included in the 2026 list compared to 2025. For…
With its longstanding emphasis on whole-person care and complex symptom management, oncology may be uniquely positioned to lead the next evolution of palliative care integration. Kim Slusser, PhD, RN, chief nursing officer at Houston-based University of Texas MD Anderson conducted…
AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in patients with advanced non-small cell lung cancer. Ceralasertib is an oral ATR kinase inhibitor designed to enhance anti-tumor immune activity, while…
Somerville, Mass.-based Mass General Brigham and Boston-based Dana-Farber Cancer Institute have developed an AI tool to predict cancer spread in patients with oropharyngeal carcinoma. The noninvasive tool uses CT imaging data to estimate the number of lymph nodes with pathologic…